CircRNA vaccine of Zika or dengue and application thereof
Through mRNA-based vaccine development, glycosylation is used to modify polypeptide analogs and circular RNA, the complex production, insufficient immunogenicity and antibody-dependent enhancement effects of existing vaccines have been solved, and simplified production, strong immune response and Effects to reduce the risk of infection.
Patent Information
- Application Number
- CN202410921551.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-10
- Publication Date
- 2024-11-22
AI Technical Summary
The existing dengue virus and Zika virus vaccines have problems such as complex production, insufficient immunogenicity, reduced effects due to antigen evolution, limited scope of application, and cold chain dependence, and cannot effectively avoid the enhanced antibody dependence effect, resulting in an increased risk of infection. .
Using mRNA-based vaccine development, mutated circular fusion epitope is constructed using linear mRNA or circular RNA to target dengue virus or Zika virus, eliminate antibody-dependent enhancement effects, and through Recombinant cells and expression vectors achieve vaccine production and expression.
It has achieved simplification of the production process, stimulated a strong and lasting immune response, reduced the risk of infection, avoided antibody-dependent enhancement effects, and was suitable for intracellular parasitic pathogens, reduced cold chain dependence, and improved the applicability and safety of the vaccine.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present application belongs to the field of biomedicine technology, and specifically relates to a circRNA vaccine for Zika or dengue and its application, and more specifically to a polypeptide analog, a nucleic acid molecule, an expression vector, a recombinant cell, a circular RNA, a linear mRNA, a vaccine, a pharmaceutical composition, or their use. Background Art
[0002] Dengue virus (DENV) and Zika virus (ZIKV) are both mosquito-borne viruses belonging to the Flaviviridae family. Dengue virus and Zika virus infection are a major public health challenge worldwide.
[0003] There is currently no effective DENV vaccine available, nor is there an approved Zika virus vaccine. A key challenge in vaccine development is to avoid the production of cross-reactive antibodies, especially the antibody-dependent enhancement (ADE) effect, which may exacerbate natural infection with other members of the Flavivirus family. The antibody-dependent enhancement effect refers to the fact that when weak neutralizing antibodies are present or the antibody concentration is low, the complex formed by the virus-binding antibody is not neutralized by the antibody under the mediation of the Fc receptor, but instead promotes the virus to enter and infect host cells, which may be related to further aggravation of the disease. The earliest report of ADE came from dengue fever, and it is of great significance to provide a method to reduce the antibody-dependent enhancement effect of dengue virus and develop a dengue vaccine that is highly immunogenic and can avoid the ADE effect during infection.
[0004] Dengue virus vaccines are generally divided into two categories: vaccines containing the entire virus (live attenuated vaccines or inactivated vaccines), or vaccines containing parts of the virus, which can be vaccines based on recombinant proteins or DNA or RNA. Vaccines based on the entire virus have several disadvantages, including the need to handle large amounts of infectious virus during the vaccine production process for inactivated vaccines, and the need for extensive safety testing of live attenuated vaccines. Vaccines based on recombinant proteins are also limited by the global production capacity of recombinant proteins, while vaccines based on DNA face difficulties related to the safe delivery of DNA and the effectiveness of generating an immune response.
[0005] The Zika virus vaccines currently in the preclinical or clinical trial stage mainly include the following categories: 1) inactivated Zika virus vaccine; 2) live attenuated Zika virus vaccine; 3) purified E protein subunit vaccine; 4) virus-like particle (VLP) vaccine; 5) DNA vector, RNA vector and recombinant virus vector vaccine. These vaccines mainly use E protein as the target antigen, trying to induce antibodies or cellular immunity specific to E protein to prevent viral infection. However, these vaccines have not yet solved the antibody-dependent enhancement effect.
[0006] Therefore, it is of great significance to provide a method to weaken the antibody-dependent enhancement effect of dengue virus or Zika virus and to develop a dengue vaccine or Zika vaccine that is highly immunogenic and can avoid the ADE effect during infection. Summary of the invention
[0007] The present application aims to solve at least one of the technical problems existing in the prior art to a certain extent. To this end, the present application provides a circRNA vaccine for Zika or dengue and its application.
[0008] This application is completed based on the following findings of the inventors:
[0009] Most current vaccines have the following problems:
[0010] 1) Complicated requirements: The production and preparation of antibody vaccines may require complex processes, including large-scale cultivation and purification of pathogens, which may increase costs and production time.
[0011] 2) Limited immunogenicity: Antibody vaccines may not stimulate a sufficiently strong and durable immune response, especially if long-term protection is required. This may require multiple doses or the use of immune adjuvants to enhance immunogenicity.
[0012] 3) Immune escape: Some pathogens may undergo antigenic evolution, causing their surface proteins to mutate, thereby escaping existing antibody recognition. This may reduce the effectiveness of antibody vaccines, especially when pathogens mutate frequently.
[0013] 4) Not applicable to some pathogens: For some pathogens, especially those without obvious surface antigens, antibody vaccines may not be effective. This may limit the scope of application of antibody vaccines. Not applicable to intracellular parasitic pathogens: Antibody vaccines mainly stimulate humoral immune responses, so the effect may be limited for intracellular parasitic pathogens, such as intracellular bacteria or parasites.
[0014] 5) Dependence on cold chain: Some antibody vaccines may be dependent on the cold chain, that is, they need to be transported and stored at lower temperatures, which may pose a challenge in some regions.
[0015] The development of mRNA-based vaccines offers a potential avenue for the use of immunogenic vaccines, and mRNA molecules are considered significantly safer than other vaccines because mRNA is more easily degraded. They are rapidly cleared from the organism and cannot integrate into the genome and affect the gene expression of the cell in an uncontrollable way. mRNA vaccines are also less likely to cause serious side effects, such as the generation of autoimmune diseases or anti-DNA antibodies. Transfection with mRNA only requires entry into the cytoplasm of the cell, which is easier to achieve than entering the nucleus.
[0016] The development of mRNA-based vaccines provides a potential way to develop immunogenic vaccines without having to deal with infectious viruses during the production process. The development and production of mRNA vaccines are relatively fast. Once the genetic sequence of the pathogen is determined, the design and production of the vaccine can be completed in a relatively short period of time, which gives mRNA vaccines a significant advantage in responding to emerging infectious diseases and epidemic outbreaks. The production process of mRNA vaccines is relatively flexible and can adapt to new virus strains or mutations by simply modifying the genetic sequence of the pathogen, which provides a rapid response to pathogen evolution. mRNA vaccines do not contain live viruses or bacteria. They only contain a portion of the genetic information of the pathogen, which is sufficient to guide the immune system to produce an immune response, so they do not cause disease, which reduces the safety risks associated with traditional vaccines. mRNA vaccines can stimulate a strong immune response, including cellular immunity and humoral immunity, which helps to establish long-term immune memory and provide lasting protection. The production process of mRNA vaccines is relatively simple and can be scaled up in a short period of time, which makes the implementation of large-scale vaccination programs more feasible. Compared with the weakened or inactivated viruses used in traditional vaccines, mRNA vaccines do not require the use of live viruses, reducing the potential risk of infection and disease.
[0017] Based on this, the present application provides a linear mRNA or circular RNA (circRNA) vaccine based on a nucleic acid molecule expressing a polypeptide analog with glycosylation modification, wherein the linear mRNA or circular RNA constructs a mutated loop fusion epitope and introduces an N-glycosylation modification site to form a novel vaccine against dengue virus (e.g., DENV-2 strain New Guinea (NGC strain) GenBank accession number: KM204118.1) or Zika virus (e.g., ZIKV-SMGC-1). The novel vaccine can eliminate the antibody-dependent enhancement effect (ADE).
[0018] Therefore, in the first aspect of the present application, the present application proposes a polypeptide analog. According to an embodiment of the present application, the polypeptide analog includes a polypeptide and a glycosylation modifier, the polypeptide (or antigen) is derived from Zika virus or dengue virus, the glycosylation modifier is located at positions 98 to 113 of the polypeptide, and positions 98 to 113 of the polypeptide are NRTWGNGCGLFGNGSL. The polypeptide analog of the present application has a glycosylation modification, and the vaccine prepared using the above polypeptide analog can eliminate the ADE effect caused by vaccination that increases the risk of infection or infection symptoms.
[0019] In the second aspect of the present application, the present application proposes a nucleic acid molecule. According to an embodiment of the present application, the nucleic acid molecule encodes the polypeptide analog described in the first aspect. According to the nucleic acid molecule of the embodiment of the present application, the above-mentioned polypeptide analog can be encoded.
[0020] In the third aspect of the present application, the present application proposes an expression vector. According to an embodiment of the present application, the expression vector carries the nucleic acid molecule described in the second aspect. The expression vector according to the embodiment of the present application can express the above-mentioned polypeptide analog.
[0021] In the fourth aspect of the present application, the present application proposes a recombinant cell. According to an embodiment of the present application, the recombinant cell carries the nucleic acid molecule described in the second aspect, or the expression vector described in the third aspect; or the recombinant cell expresses the polypeptide analog described in the first aspect. The recombinant cell can effectively express the aforementioned polypeptide analog in the recombinant cell under suitable conditions.
[0022] In the fifth aspect of the present application, the present application proposes a circular RNA. According to an embodiment of the present application, the circular RNA includes a first nucleic acid sequence encoding a polypeptide; wherein the polypeptide is derived from Zika virus or dengue virus, and the 98th to 113th positions of the polypeptide are NRTWGNGCGLFGNGSL. The circular RNA of the present application can be expressed in vivo to obtain a polypeptide with glycosylation modification, and the use of the circular RNA as a vaccine can eliminate the ADE effect caused by vaccination that increases the risk of infection or infection symptoms.
[0023] In the sixth aspect of the present application, the present application proposes a linear mRNA. According to an embodiment of the present application, the linear mRNA includes a nucleic acid sequence A encoding a polypeptide; wherein the polypeptide is derived from Zika virus or dengue virus, and the 98th to 113th positions of the polypeptide are NRTWGNGCGLFGNGSL. The linear mRNA of the present application can be expressed in vivo to obtain a polypeptide with glycosylation modification, and the use of the linear mRNA as a vaccine can eliminate the ADE effect caused by vaccination that increases the risk of infection or infection symptoms.
[0024] In the seventh aspect of the present application, the present application proposes a vaccine. According to an embodiment of the present application, the vaccine comprises the polypeptide analog described in the first aspect, the circular RNA described in the fifth aspect, or the linear mRNA described in the sixth aspect. The vaccine of the present application is a glycosylated polypeptide analog or a polypeptide analog with glycosylation modification that can be expressed in vivo, and the vaccine can eliminate the ADE effect of increasing the risk of infection or infection symptoms caused by vaccination.
[0025] In the eighth aspect of the present application, the present application proposes a pharmaceutical composition. According to an embodiment of the present application, the pharmaceutical composition comprises the polypeptide analogue described in the first aspect, the circular RNA described in the fifth aspect, the linear mRNA described in the sixth aspect, or the vaccine described in the seventh aspect. The composition of the present application can effectively prevent or treat related diseases caused by Zika virus or dengue virus infection, especially can eliminate the ADE effect caused by vaccination that increases the risk of infection or infection symptoms.
[0026] In the ninth aspect of the present application, the present application proposes the use of the polypeptide analogue described in the first aspect, the circular RNA described in the fifth aspect, the linear mRNA described in the sixth aspect, or the vaccine described in the seventh aspect in the preparation of a drug, wherein the drug is used to prevent or treat related diseases caused by Zika virus or dengue virus infection.
[0027] Additional aspects and advantages of the present application will be given in part in the description below, and in part will become apparent from the description below, or will be learned through the practice of the present application. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] The above and / or additional aspects and advantages of the present application will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0029] Figure 1 The schematic diagram of the circular RNA construction in Example 1 of the present application and the schematic diagram of the mRNA vaccine preparation in Example 2;
[0030] FIG2 is the result of detecting DENV-2-E binding antibody and true virus neutralizing antibody titers in each group of mice in Example 3 of the present application;
[0031] Figure 3 The cellular immune response results after mice were immunized with DENV-2 related vaccines in Example 3 of the present application;
[0032] Figure 4 The weight change curve after DENV-2 virus challenge (A) and the mortality result after DENV-2 virus challenge (B) in Example 4 of the present application;
[0033] Figure 5The weight change curve after ZIKV-SMGC-1 virus challenge (A) and the mortality result after ZIKV-SMGC-1 virus challenge (B) in Example 4 of the present application;
[0034] Figure 6 DENV in Example 5 of this application WT 、DENV NLG Experimental results of vaccine-immunized mice in resisting viremia caused by DENV-2 virus infection;
[0035] Figure 7 For the circRNA in Example 5 of this application WT , circRNA NLG , L-RNA NLG Experimental results of vaccine-immunized mice in resisting viremia caused by ZIKV-SMGC-1 virus infection;
[0036] Figure 8 This is the neutralizing antibody titer result in the serum one day before the detection of DENV-2 virus in Example 6 of the present application;
[0037] Fig. 9 DENV in Example 6 of this application WT 、DENV NLG The results of the viral load test in the spleen of vaccine-immunized mice after resisting DENV-2 virus attack;
[0038] Fig.10 For the circRNA in Example 6 of this application WT , circRNA NLG , L-RNA NLG The results of the viral load test in the spleen of vaccine-immunized mice after resisting ZIKV-SMGC-1 virus attack;
[0039] Fig.11 For the circRNA in Example 7 of this application WT , circRNA NLG , L-RNA NLG Serum binding antibody (A) and neutralizing antibody titers (B) of vaccine-immunized mice on day 28;
[0040] Fig.12 For the circRNA in Example 7 of this application WT , circRNA NLG , L-RNA NLG The results of the experiment on the viral load detection in the fetal head, fetal body, placenta, maternal brain and maternal spleen after the vaccine-immunized mice resisted the ZIKV-SMGC-1 virus attack during pregnancy;
[0041] Fig.13 DENV in Example 8 of this application WT 、DENV NLG The serum of vaccine-immunized mice was tested by ELISA for binding to Zika virus E protein and infection results with ZIKV-SMGC-1 virus on K562 cells;
[0042] Fig.14 For the circRNA in Example 8 of this application WT , circRNA NLG , L-RNA NLG The results of the ADE effect experiment of the sera of vaccine-immunized mice on DENV-2-infected K562 cells;
[0043] Fig.15 For the circRNA in Example 8 of this application WT , circRNA NLG , L-RNA NLG The sera of vaccine-immunized BALB / c mice were tested for binding to the E proteins of DENV2, DENV3, and DENV4 by ELISA;
[0044] Fig.16 DENV in Example 9 of this application WT 、DENV NLG The results of the ADE effect experiment on Zika virus (ZIKV-SMGC-1) infection after the serum of vaccine-immunized BALB / c mice was passively transferred to Ifnar1- / - mice;
[0045] Fig.17 DENV in Example 9 of this application WT 、DENV NLG Results of viremia detection on days 1 and 3 of Zika virus (ZIKV-SMGC-1) infection after passive transfer of sera from vaccine-immunized BALB / c mice to Ifnar1- / - mice;
[0046] Fig.18 For the circRNA in Example 9 of this application WT , circRNA NLG , L-RNA NLG The results of the ADE effect experiment on DENV-2 infection after the serum of vaccine-immunized BALB / c mice was passively transferred to Ifnar1- / - mice. DETAILED DESCRIPTION
[0047] The embodiments of the present application are described in detail below. The embodiments described below are exemplary and are only used to explain the present application, and cannot be understood as limiting the present application.
[0048] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of this application, unless otherwise specified, the meaning of "plurality" is two or more.
[0049] This application details
[0050] Definitions and general terms
[0051] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0052] In order to make the present application more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present application belongs. The abbreviations for amino acid residues are standard 3-letter and / or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids (i.e., amino acids in the left-handed configuration).
[0053] In this document, the terms "include" or "comprising" are open expressions, that is, including the contents specified in the present application but not excluding other contents.
[0054] As used herein, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0055] As used herein, the term "polypeptide analogs" refers to molecules having structures and functions similar to those of natural polypeptides, which include other structures besides amino acids, such as glycosylation modifications.
[0056] As used herein, the terms "nucleic acid", "nucleic acid molecule", "nucleotide sequence" and "nucleic acid sequence" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof.
[0057] In this article, the term "expression vector" generally refers to a nucleic acid molecule that can be inserted into a suitable host and replicates itself, and the inserted nucleic acid molecule is transferred into and / or between cells or hosts. The vector may include a vector that is mainly used to insert DNA or RNA into a cell, a vector that is mainly used to replicate DNA or RNA, and an expression vector that is mainly used for transcription and / or translation of DNA or RNA. The expression vector also includes a vector with a variety of the above functions. The expression vector can be a polynucleotide that can be transcribed and translated into a polypeptide when introduced into a suitable cell or host. Typically, the expression vector can produce a desired expression product by culturing a suitable cell or host containing the vector.
[0058] In this article, the term "recombinant cell" generally refers to the use of genetic engineering technology or cell fusion technology to modify or reorganize the genetic material of the host cell to obtain a cell with a unique trait of stable inheritance. Wherein, the term "host cell" refers to a prokaryotic cell or eukaryotic cell that can be introduced into a recombinant vector. The terms "transformed" or "transfected" used herein refer to the introduction of nucleic acids (such as vectors) into cells by various techniques known in the art. Suitable host cells can be transformed or transfected with the DNA sequence of the present application, and can be used for the expression and / or secretion of target proteins. Examples of suitable host cells that can be used for the present application include immortalized hybridoma cells, NS / 0 myeloma cells, 293 cells, Chinese hamster ovary (CHO) cells, HeLa cells, Cap cells (cells derived from human amniotic fluid) and CoS cells.
[0059] In this context, the term "vaccine" is understood to refer to an immunologically active pharmaceutical preparation. In certain embodiments, the vaccine induces adaptive immunity when administered to a host. The vaccine preparation may further comprise a pharmaceutical carrier, which may be designed for a specific mode of administration of the vaccine.
[0060] As used herein, the terms "group I intron" and "group I catalytic intron" are used interchangeably to refer to a self-splicing ribozyme that catalyzes its own excision from an RNA precursor. Group I introns contain two segments, a 5' catalytic group I intron segment and a 3' catalytic group I intron segment, which retain their folding and catalytic functions (i.e., self-splicing activity). The terms "5' exon sequence" and "3' exon sequence" as used herein are labeled according to the order of the exon relative to the group I intron in its natural environment.
[0061] In this article, "pharmaceutical composition" may refer to a composition used for the treatment of a disease, and may also be used for in vitro culture experiments of cells. When used for the treatment of a disease, the term "pharmaceutical composition" generally refers to a unit dosage form, and may be prepared by any of the methods well known in the pharmaceutical field. All methods include the step of combining the active ingredient with an excipient that constitutes one or more accessory ingredients. Typically, the composition is prepared by uniformly and fully combining the active vaccine with a liquid excipient, a finely divided solid excipient, or both.
[0062] In this article, the term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammals treated therewith. Preferably, "pharmaceutically acceptable" as described in this application refers to those approved by federal regulatory agencies or national governments or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeias for use in animals, particularly humans.
[0063] In this article, the term "pharmaceutically acceptable excipient" may include any solvent, stabilizer, diluent or other liquid excipient, etc., suitable for a specific target dosage form. In addition to any conventional excipients incompatible with the vaccine of the present application, such as any adverse biological effects produced or interactions with any other components of the pharmaceutically acceptable composition in a harmful manner, their use is also within the scope of the present application.
[0064] In this article, the term "administration" refers to the introduction of a predetermined amount of material into a patient by a certain suitable method. The vaccine of the present application can be administered by any common route, as long as it can reach the expected tissue. The various modes of administration are expected to include peritoneal, intravenous, intramuscular, subcutaneous injections, etc., but the application is not limited to these exemplified modes of administration. Preferably, the vaccine of the present application or pharmaceutical composition are administered by intravenous or subcutaneous injection.
[0065] As used herein, the term "treatment" refers to the use of drugs to obtain the desired pharmacological and / or physiological effects. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in individuals who are susceptible to the disease but have not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the progression of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a vaccine to an individual to treat, cure, alleviate, improve, reduce or inhibit an individual's disease, including but not limited to administering a vaccine described herein to an individual in need.
[0066] Detailed description of the circRNA vaccine for Zika or dengue and its application
[0067] The present application proposes a polypeptide analog, a nucleic acid molecule, an expression vector, a recombinant cell, a circular RNA, a linear mRNA, a vaccine, a pharmaceutical composition, or uses thereof, which will be described in detail below.
[0068] Peptide analogs
[0069] In the first aspect of the present application, the present application proposes a polypeptide analog. According to an embodiment of the present application, the polypeptide analog includes a polypeptide and a glycosylation modifier, the polypeptide is derived from Zika virus or dengue virus, the glycosylation modifier is located at positions 98 to 113 of the polypeptide, and positions 98 to 113 of the polypeptide are NRTWGNGCGLFGNGSL. The polypeptide analog of the present application has a glycosylation modification, and the vaccine prepared using the above polypeptide analog can eliminate the ADE effect caused by vaccination that increases the risk of infection or infection symptoms.
[0070] According to an embodiment of the present application, the polypeptide includes the E protein of Zika virus or dengue virus.
[0071] According to an embodiment of the present application, the polypeptide is selected from the M protein and E protein of Zika virus, or the M protein and E protein of dengue virus.
[0072] According to an embodiment of the present application, the polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or 2.
[0073] Glycosylated ZIKV-M / E protein (SEQ ID NO: 1):
[0074] VTLPSHSTRKLQTRSQTWLESREYTKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYLDKQSDTQYVCKRTLVNRTWGNGCGLFGNGSLVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLMCLALGGVLIFLSTAVSA;
[0075] Glycosylated DENV-2-M / E protein (SEQ ID NO:2):
[0076] .
[0077] In this article, the term "glycosylation modification" should be interpreted in a broad sense, referring to any sugar molecule or its derivative that can be linked to N in a polypeptide, without limitation to the specific type, and all are within the scope of protection of this application.
[0078] According to an embodiment of the present application, the glycosylation modification is an N-acetylneuraminic acid modification.
[0079] In an optional embodiment of the present application, the N-acetylneuraminic acid modifier is usually linked to the nitrogen group of the 98th N side chain and / or the nitrogen group of the 110th N side chain via a β-glycosylamide linker.
[0080] In an optional embodiment of the present application, the N-acetylneuraminic acid modifier is typically linked to the nitrogen group of the N side chain at position 98 via a β-glycosylamide linker, and the N-acetylneuraminic acid modifier is typically linked to the nitrogen group of the N side chain at position 110 via a β-glycosylamide linker.
[0081] In an optional embodiment of the present application, the N-acetylneuraminic acid modifier is usually linked to the nitrogen group of the N side chain at position 98 via a β-glycosylamide linker.
[0082] In an optional embodiment of the present application, the N-acetylneuraminic acid modifier is usually linked to the nitrogen group of the N side chain at position 110 via a β-glycosylamide linker.
[0083] In this article, glycosylation can be achieved by any means known in the art. In some embodiments, the glycosylation is achieved by the expression of a binding polypeptide capable of N-glycosylation in a cell. Any natural or engineered cell (e.g., prokaryotic or eukaryotic) can be used. In general, mammalian cells are used to achieve glycosylation. Exemplarily, N-glycans produced in mammalian cells are generally referred to as complex N-glycans (see, e.g., Drickamer K, Taylor ME (2006). Introduction to Glycobiology, 2nd edition, which is incorporated herein by reference in its entirety). Complex N-glycans have at least one branch, and preferably at least two, terminating in alternating GlcNAc and galactose (Gal) residues of the oligosaccharide, such as, for example: NeuNAc-; NeuAcα2, 6GalNAcα1-; NeuAcα2, 3Galβ1, 3GalNAcα1- and NeuAcα2, 3 / 6Galβ1, 4GlcNAcβ1; in addition, sulfates may be present on galactose, GalNAc and GlcNAc residues, and phosphates may be present on mannose residues. Complex N-glycans may also have bisecting GlcNAc and interchain substitutions of core fucose (Fuc).
[0084] Additionally or alternatively, glycosylation can be obtained or modified enzymatically in vitro. For example, one or more glycosyltransferases can be used to add specific sugar residues to N-98 and / or N-110, and one or more glycosidases can be used to remove unwanted sugars from N-linked glycans, such enzymatic methods are known in the art.
[0085] Therefore, when preparing a glycosylation-modified protein (such as a protein vaccine), the manner of implementing glycosylation is not specifically limited and is within the scope of protection of this application.
[0086] Nucleic acid molecules, expression vectors, recombinant cells
[0087] In the second aspect of the present application, the present application proposes a nucleic acid molecule. According to an embodiment of the present application, the nucleic acid molecule encodes the polypeptide analog described in the first aspect. According to the nucleic acid molecule of the embodiment of the present application, the above-mentioned polypeptide analog can be encoded.
[0088] According to an embodiment of the present application, the nucleic acid molecule is DNA or mRNA.
[0089] According to an embodiment of the present application, the mRNA is selected from linear mRNA or circular RNA.
[0090] It should be noted that, for the nucleic acid mentioned herein, it should be understood by those skilled in the art that it actually includes any one or two of the complementary double strands. For convenience, in this article, although only one strand is provided in most cases, another strand complementary thereto is actually disclosed. In addition, the molecular sequence in this application includes a DNA form or an mRNA form, and disclosing one of them means that the other is also disclosed.
[0091] In the third aspect of the present application, the present application proposes an expression vector. According to an embodiment of the present application, the expression vector carries the nucleic acid molecule described in the second aspect. When the above-mentioned nucleic acid molecule is connected to the above-mentioned expression vector, the nucleic acid molecule can be directly or indirectly connected to the control element on the expression vector, as long as these control elements can control the translation and expression of the nucleic acid molecule. Of course, these control elements can come directly from the expression vector itself, or they can be exogenous, that is, not from the expression vector itself. Of course, the nucleic acid molecule can be operably connected to the control element.
[0092] Herein, "operably connected" means connecting the exogenous gene to the vector so that the control elements in the expression vector, such as transcription control sequences and translation control sequences, etc., can play their intended functions of regulating the transcription and translation of the exogenous gene. Commonly used expression vectors can be, for example, plasmids, bacteriophages, etc. After the vectors of some specific embodiments of the present application are introduced into suitable recipient cells, the expression of the aforementioned polypeptide analogs can be effectively achieved under the mediation of the regulatory system, thereby achieving a large amount of in vitro acquisition of polypeptide analogs. The obtained polypeptide analogs can be used for the preparation of subsequent protein vaccines.
[0093] According to the embodiments of the present application, the expression vector may refer to a cloning vector, which can be obtained by operably connecting the nucleic acid molecule to a commercially available vector (such as a plasmid or a viral vector). The vector in the present application is not particularly limited, and commonly used plasmids can be used, such as pSeTag2, PEE14, pMH3, etc.
[0094] In some optional embodiments of the present application, the expression vector is a eukaryotic expression vector, a prokaryotic expression vector, a virus or a bacteriophage.
[0095] In some optional embodiments of the present application, the expression vector is selected from a prokaryotic expression vector or a eukaryotic expression vector.
[0096] In the fourth aspect of the present application, the present application proposes a recombinant cell. According to an embodiment of the present application, the recombinant cell carries the nucleic acid molecule described in the second aspect, or the expression vector described in the third aspect; or the recombinant cell expresses the polypeptide analog described in the first aspect. The recombinant cell can effectively express the aforementioned polypeptide analog in the recombinant cell under suitable conditions.
[0097] According to an embodiment of the present application, the recombinant cell is obtained by introducing the aforementioned vector into a cell or a host.
[0098] It should be noted that the recombinant cells of the present application are not particularly limited and can be prokaryotic cells, eukaryotic cells or bacteriophages. The prokaryotic cells can be Escherichia coli, Bacillus subtilis, Streptomyces or Proteus mirabilis, etc. The eukaryotic cells include fungi such as Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trichoderma, insect cells such as armyworms, plant cells such as tobacco, and mammalian cells such as BHK cells, CHO cells, COS cells, and myeloma cells.
[0099] In an optional embodiment of the present application, the recombinant cell is a mammalian cell, including a BHK cell, a CHO cell, a NSO cell or a COS cell, and does not include an animal germ cell, a fertilized egg or an embryonic stem cell.
[0100] It should be noted that the "suitable conditions" described in this application refer to conditions suitable for the expression of the polypeptide analogs described in this application. It is easy for those skilled in the art to understand that the conditions suitable for the expression of the polypeptide analogs include, but are not limited to, suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy cell states, suitable cell density, suitable cell culture environment, and suitable cell culture time. "Suitable conditions" are not particularly limited, and those skilled in the art can optimize the most suitable conditions for the expression of the polypeptide analogs according to the specific environment of the laboratory.
[0101] Circular RNA
[0102] In a fifth aspect of the present application, the present application proposes a circular RNA. According to an embodiment of the present application, the circular RNA comprises a first nucleic acid sequence encoding a polypeptide; wherein the polypeptide is derived from Zika virus or dengue virus, and positions 98 to 113 of the polypeptide are NRTWGNGCGLFGNGSL.
[0103] The circular RNA of the present application can be expressed in vivo to obtain a polypeptide with glycosylation modification. Using the circular RNA as a vaccine can eliminate the ADE effect caused by vaccination that increases the risk of infection or infection symptoms. In addition, the circular RNA of the present application can produce more antigenic proteins in cells and prolong the expression of antigenic proteins, thereby causing the body to produce a persistent and potent antibody response, which can more effectively activate the immune system, thereby inducing a stronger immune response. In addition, since circular RNA does not exist in cells for a long time, the immune system may have a low tolerance to it, which further helps to maintain a longer immune effect.
[0104] According to an embodiment of the present application, the polypeptide includes the E protein of Zika virus or dengue virus.
[0105] According to an embodiment of the present application, the polypeptide is selected from the M protein and E protein of Zika virus, or the M protein and E protein of dengue virus.
[0106] According to an embodiment of the present application, the polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or 2.
[0107] According to an embodiment of the present application, the first nucleic acid sequence has a nucleotide sequence as shown in SEQ ID NO: 3 or 4.
[0108] In an optional embodiment of the present application, the nucleotide sequence shown in SEQ ID NO:3 is used to encode the amino acid sequence shown in SEQ ID NO:1; the nucleotide sequence shown in SEQ ID NO:4 is used to encode the amino acid sequence shown in SEQ ID NO:2.
[0109] Nucleotide sequence of glycosylated ZIKV-M / E protein (SEQ ID NO: 3):
[0110]
[0111] Nucleotide sequence of glycosylated DENV-2-M / E protein (SEQ ID NO:4):
[0112] TGTGCAGGAGCATCAGTGGCCCTGGTTCCTCATGTTGGTATGGGCCTCGAAACCCGAACTGAA
[0113] ACGTGGATGTCTTCTGAAGGAGCTTGGAAGCATGTCCAGCGTATCGAGACTTGGATTCTGCGCCAC
[0114] CCCGGTTTCACAATGATGGCAGCCATTTTGGCCTATACCATTGGCACTACACACTTCCAGAGGGCTT
[0115] TGATCTTCATCTTGCTCACTGCTGTGACACCATCCATGACCATGAGATGCATCGGTATGTCCAACCGT
[0116] GACTTTGTGGAAGGGGTTTCAGGGGGGTCTTGGGTGGACATCGTGCTAGAACATGGCAGCTGTGT
[0117] GACAACTATGGCTAAGAACAAGCCTACCCTGGATTTTGAGCTGATCAAGACTGAGGCGAAGCAAC
[0118] CTGCCACTTTGAGAAAGTACTGCATTGAGGCAAAACTGACCAACACAACCACGGAAAGCCGCTGC
[0119] CCCACACAGGGCGAGCCTTCGTTAAATGAAGAGCAGGACAAGCGCTTTGTGTGCAAACACAGCAT
[0120] GGTAAACAGGACTTGGGGCAATGGCTGTGGGCTGTTTGGGAATGGAAGTATTGTGACCTGCGCTAT
[0121] GTTCCGATGTAAGAAAAACATGGAAGGCAAAGTCGTCCAGCCAGAAAATCTCGAGTACACCATAG
[0122] TCATAACCCCCCACTCCGGAGAGGAGCATGCTGTTGGGAATGATACAGGTAAGCACGGGAAAGAG
[0123] ATAAAAATCACACCACAGAGCTCTATCACAGAAGCAGAGCTGACGGGCTATGGAACTGTAACCATG
[0124] GAGTGTTCACCACGGACGGGTCTGGACTTCAACGAGATGGTGCTTCTCCAAATGGAGAACAAAGC
[0125] CTGGCTGGTCCATAGGCAGTGGTTCCTAGATCTGCCTCTCCCCTGGCTCCCTGGGGCCGACACCCA
[0126] AGGTAGCAACTGGATCCAGAAGGAGACGCTTGTTACTTTCAAGAATCCACACGCCAAAAAGCAGG
[0127] ATGTGGTGGTTCTGGGTTCTCAGGAGGGAGCTATGCACACTGCCTTGACAGGCGCAACAGAGATTC
[0128] AAATGAGCAGTGGAAATCTGCTGTTCACTGGACATCTAAAGTGCAGGCTCAGGATGGATAAACTGC
[0129] AGCTGAAGGGCATGTCATACAGTATGTGTACCGGGAAATTTAAAGTGGTCAAGGAAATTGCCGAAA
[0130] CCCAGCATGGTACTATCGTCATTCGGGTGCAATATGAGGGCGATGGATCCCCGTGTAAAATTCCCTT
[0131] CGAGATCATGGACCTGGAAAAAAGACACGTGCTGGGGCGGTTGATAACAGTGAATCCTATAGTTAC
[0132] CGAGAAGGACTCACCGGTCAACATTGAGGCTGAACCCCCATTTGGAGACTCTTACATTATCATCGG
[0133] GGTCGAGCCAGGCCAGCTCAAGTTGAACTGGTTTAAAAAAGGGTCCAGTATTGGACAGATGTTTG
[0134] AAACAACAATGCGGGGTGCAAAGAGAATGGCGATTTTAGGGGACACTGCTTGGGATTTCGGCTCC
[0135] CTTGGAGGCGTCTTCACCAGTATTGGAAAGGCTTTGCACCAGGTTGTTTGGCGCCATCTATGGTGCG
[0136] GCCTTCAGCGGAGTTAGCTGGACCATGAAGATCCTCATCGGCGTGATCATCACCTGGATCGGCATG
[0137] AACTCCCGATCTACATCATTAAGTGTGACGCTTGTACTTGTTGGAATAGTAACACTTTACCTGGGCGTCATGGTTCAAGCATGA.
[0138] According to an embodiment of the present application, it further includes a second nucleic acid sequence, the 3' end of the second nucleic acid sequence is connected to the 5' end of the first nucleic acid sequence, and the second nucleic acid sequence is used to encode a signal peptide.
[0139] According to an embodiment of the present application, the signal peptide is a JEV signal peptide.
[0140] According to an embodiment of the present application, the signal peptide has an amino acid sequence as shown in SEQ ID NO:5.
[0141] MWLVSLAIVTACAGA (SEQ ID NO:5).
[0142] According to an embodiment of the present application, the first nucleic acid sequence signal peptide has a nucleotide sequence as shown in SEQ ID NO:16.
[0143] In an optional embodiment of the present application, the nucleotide sequence shown in SEQ ID NO:16 is used to encode the amino acid sequence shown in SEQ ID NO:6.
[0144] ATGTGGCTGGTGTCCCTGGCTATCGTGACCGCCTGCGCCGGCGCC (SEQ ID NO: 16).
[0145] According to an embodiment of the present application, it further includes a promoter, which is located at the 5' end of the second nucleic acid sequence.
[0146] According to an embodiment of the present application, the promoter is a T7 promoter.
[0147] According to an embodiment of the present application, the promoter has a nucleotide sequence as shown in SEQ ID NO:17.
[0148] TAATACGACTCACTATAGG (SEQ ID NO: 17).
[0149] According to an embodiment of the present application, it further comprises an IRES sequence, wherein the 3' end of the IRES sequence is connected to the 5' end of the second nucleic acid sequence.
[0150] According to an embodiment of the present application, the IRES sequence is selected from at least one of the IRES sequence of CVB3 virus, the IRES sequence of EV71 virus, the IRES sequence of EMCV virus, the IRES sequence of PV virus, and the IRES sequence of CSFV virus.
[0151] According to an embodiment of the present application, the IRES sequence is selected from the IRES sequence of the EMCV virus.
[0152] According to an embodiment of the present application, the IRES sequence has a nucleotide sequence as shown in SEQ ID NO:6.
[0153] (SEQ ID NO:6).
[0154] According to an embodiment of the present application, it further comprises a polyAC sequence or a polyA sequence, wherein the 3' end of the polyA sequence is connected to the 5' end of the IRES sequence, and the 5' end of the polyAC sequence is connected to the 3' end of the IRES sequence.
[0155] In an optional embodiment of the present application, the polyAC sequence (ie, spacer2) has a nucleotide sequence as shown in SEQ ID NO:9.
[0156] AAAAAACAAAAAACAAAAC (SEQ ID NO:9).
[0157] In an optional embodiment of the present application, the polyA sequence (ie, spacer1) has a nucleotide sequence as shown in SEQ ID NO:10.
[0158] AAAAACAAAAAACAAAAAAAACAAAAAAAAAACAAAAAAACAAAAC (SEQ ID NO: 10).
[0159] According to an embodiment of the present application, it further includes a 3' exon sequence and a 5' exon sequence, wherein the 3' exon sequence is located at the 5' end of the first nucleic acid sequence and is used to be recognized by the 3' catalytic group I intron fragment, and the 5' exon sequence is located at the 3' end of the first nucleic acid sequence and is used to be recognized by the 5' catalytic group I intron fragment.
[0160] According to an embodiment of the present application, the 3' exon sequence (ie, Linker2) has a nucleotide sequence as shown in SEQ ID NO:7.
[0161] AGACGCTACGGACTT (SEQ ID NO:7).
[0162] According to an embodiment of the present application, the 5' exon sequence (ie, Linker1) has a nucleotide sequence as shown in SEQ ID NO:8.
[0163] AAAATCCGTTGACCTTAAACGGTCGTGTGGGTTCAAGTCCCTCCACCCCCA (SEQ ID NO: 8).
[0164] According to an embodiment of the present application, it further comprises a 5' homology arm and a 3' homology arm, wherein the 5' homology arm is located between the 3' exon sequence and the polyA sequence, and the 3' homology arm is located between the 5' exon sequence and the polyAC sequence.
[0165] According to an embodiment of the present application, the 5' homology arm has a nucleotide sequence as shown in SEQ ID NO:18.
[0166] CGCCGGAAACGCAATAGCCG (SEQ ID NO: 18).
[0167] According to an embodiment of the present application, the 3' homology arm has a nucleotide sequence as shown in SEQ ID NO:19.
[0168] GGCTATTATGCGTTACCGGCG (SEQ ID NO: 19).
[0169] Linear mRNA
[0170] In the sixth aspect of the present application, the present application proposes a linear mRNA. According to an embodiment of the present application, the linear mRNA includes a nucleic acid sequence A encoding a polypeptide; wherein the polypeptide is derived from Zika virus or dengue virus, and the 98th to 113th positions of the polypeptide are NRTWGNGCGLFGNGSL. The linear mRNA of the present application can be expressed in vivo to obtain a polypeptide with glycosylation modification, and the use of the linear mRNA as a vaccine can eliminate the ADE effect caused by vaccination that increases the risk of infection or infection symptoms.
[0171] According to an embodiment of the present application, the polypeptide includes the E protein of Zika virus or dengue virus.
[0172] According to an embodiment of the present application, the polypeptide is selected from the M protein and E protein of Zika virus, or the M protein and E protein of dengue virus.
[0173] According to an embodiment of the present application, the polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or 2.
[0174] According to an embodiment of the present application, the nucleic acid sequence A has a nucleotide sequence as shown in SEQ ID NO: 3 or 4.
[0175] According to an embodiment of the present application, it further includes a nucleic acid sequence B, the 3' end of the nucleic acid sequence B is connected to the 5' end of the nucleic acid sequence A, and the nucleic acid sequence B is used to encode a signal peptide.
[0176] According to an embodiment of the present application, the signal peptide is a JEV signal peptide.
[0177] According to an embodiment of the present application, the signal peptide has an amino acid sequence as shown in SEQ ID NO:5.
[0178] According to an embodiment of the present application, it further includes a 5' UTR sequence and a 3' UTR sequence, wherein the 5' UTR sequence is connected to the 5' end of the nucleic acid sequence B, and the 3' UTR sequence is connected to the 3' end of the nucleic acid sequence A.
[0179] According to an embodiment of the present application, the 5'-end UTR sequence has a nucleotide sequence as shown in SEQ ID NO:11.
[0180] GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC (SEQ ID NO: 11).
[0181] According to an embodiment of the present application, the 3'-end UTR sequence has a nucleotide sequence as shown in SEQ ID NO:12.
[0182] UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGA (SEQ ID NO: 12).
[0183] According to an embodiment of the present application, it further includes a promoter, which is located at the 5' end of the 5' UTR sequence.
[0184] According to an embodiment of the present application, the promoter is a T7 promoter.
[0185] According to an embodiment of the present application, a polyA sequence is further included.
[0186] vaccine
[0187] In the seventh aspect of the present application, the present application proposes a vaccine. According to an embodiment of the present application, the vaccine comprises the polypeptide analog described in the first aspect, the circular RNA described in the fifth aspect, or the linear mRNA described in the sixth aspect. The vaccine of the present application is a glycosylated polypeptide analog or a polypeptide analog with glycosylation modification that can be expressed in vivo, and the vaccine can eliminate the ADE effect of increasing the risk of infection or infection symptoms caused by vaccination.
[0188] In some optional embodiments of the present application, the vaccine is a circular RNA vaccine or a linear mRNA vaccine.
[0189] In some optional embodiments of the present application, the vaccine is a circular RNA vaccine. The production and preparation process of the vaccine prepared using circular RNA is relatively simple, which may help to improve the production efficiency of the circular RNA vaccine. In addition, unlike DNA vaccines, circular RNA vaccines are generally not integrated into the host genome, reducing concerns about integration risks. The inventors further discovered that circular RNA has higher stability than linear mRNA, and thus, vaccines prepared using circular RNA can improve the storage and transportation effects of vaccines and reduce dependence on cold chains.
[0190] According to an embodiment of the present application, it further includes liposomes, neutral lipids, hydrophobic lipids, and PEG-lipids.
[0191] According to an embodiment of the present application, the liposome is a nanoparticle liposome (iLAND).
[0192] According to an embodiment of the present application, the neutral lipid comprises at least one selected from the following:
[0193] Distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DPPC), phosphatidylcholine (POPC), dioleoylphosphatidylethanolamine (DOPE), dilauroylphosphatidylcholine (DLPC), diethyl pyrocarbonate (DEPC), dimyristoylphosphatidylcholine (DMPC), and egg yolk phosphatidylcholine (EPC).
[0194] According to an embodiment of the present application, the neutral lipid is selected from dioleoylphosphatidylethanolamine.
[0195] According to an embodiment of the present application, the hydrophobic lipid is selected from sterols.
[0196] According to an embodiment of the present application, the hydrophobic lipid is selected from cholesterol.
[0197] According to an embodiment of the present application, the PEG-lipid is selected from at least one of the following:
[0198] Dipalmitoylphosphatidylethanolamine-PEG, distearoylphosphatidylethanolamine-PEG, dimyristylglycerol, and dimethacrylate.
[0199] According to an embodiment of the present application, the PEG-lipid is selected from dimyristylglycerol and / or dimethacrylate.
[0200] According to an embodiment of the present application, the molar ratio of the liposome, the neutral lipid, the hydrophobic lipid, and the PEG-lipid is (20-80):(5-30):(10-50):(0.5-5).
[0201] According to an embodiment of the present application, the molar ratio of the liposome, the neutral lipid, the hydrophobic lipid, and the PEG-lipid is (20-80): (5-20): (30-50): (0.5-2).
[0202] According to an embodiment of the present application, the molar ratio of the liposome, the neutral lipid, the hydrophobic lipid, and the PEG-lipid is (30-60): (5-15): (40-50): (0.5-2).
[0203] Composition
[0204] In the eighth aspect of the present application, the present application proposes a composition. According to an embodiment of the present application, the composition includes the polypeptide analog described in the first aspect, the circular RNA described in the fifth aspect, the linear mRNA described in the sixth aspect, or the vaccine described in the seventh aspect. The composition of the present application can effectively prevent or treat related diseases caused by Zika virus or dengue virus infection, especially can eliminate the ADE effect caused by vaccination that increases the risk of infection or infection symptoms.
[0205] In an optional embodiment of the present application, the composition is a pharmaceutical composition.
[0206] According to an embodiment of the present application, the composition further includes a pharmaceutically acceptable excipient.
[0207] According to an embodiment of the present application, the excipients include but are not limited to one or more pharmaceutically acceptable diluents, stabilizers or pH regulators.
[0208] According to an embodiment of the present application, the composition is an injection.
[0209] It should be noted that the composition includes combinations separated in time and / or space, as long as they can work together to achieve the purpose of the present application. For example, the components contained in the composition can be administered to the subject as a whole, or separately. When the components contained in the composition are administered to the subject separately, each component can be administered to the subject simultaneously or sequentially.
[0210] The composition of the present application contains a safe and effective amount of the active ingredient of the present application and a pharmaceutically acceptable adjuvant. Such adjuvants include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. Usually, the pharmaceutical preparation should match the mode of administration, and the dosage form of the composition of the present application is an injection. For example, it is prepared by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants. The composition is preferably manufactured under sterile conditions.
[0211] The effective amount of the active ingredients described herein may vary with the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). For example, several divided doses may be given daily, or the dose may be reduced proportionally, depending on the urgency of the treatment condition.
[0212] The pharmaceutically acceptable excipients described in the present application include (but are not limited to): water, saline, liposomes, lipids, peptides, cellulose, nanogels, or combinations thereof. The choice of carrier should match the mode of administration, which are well known to those of ordinary skill in the art.
[0213] use
[0214] In the ninth aspect of the present application, the present application proposes the use of the polypeptide analogue described in the first aspect, the circular RNA described in the fifth aspect, the linear mRNA described in the sixth aspect, or the vaccine described in the seventh aspect in the preparation of a drug, wherein the drug is used to prevent or treat related diseases caused by Zika virus or dengue virus infection.
[0215] method
[0216] In the tenth aspect of the present application, the present application proposes a method for preventing or treating related diseases caused by Zika virus or dengue virus infection. According to an embodiment of the present application, the method comprises: administering to a subject a pharmaceutically acceptable effective amount of the polypeptide analogue described in the first aspect, the circular RNA described in the fifth aspect, the linear mRNA described in the sixth aspect, the vaccine described in the seventh aspect, or the composition described in the eighth aspect. Thus, the related diseases caused by Zika virus or dengue virus infection can be effectively prevented or treated.
[0217] It should be noted that the terms "subject", "individual" and "patient" are used interchangeably herein and refer to a mammal that is evaluated for treatment and / or treated. In one embodiment, the mammal is a human. The terms "subject", "individual" and "patient" include, but are not limited to, individuals with cancer, individuals with autoimmune diseases, individuals with pathogen infection, etc. The subject can be a human, but also includes other mammals, particularly mammals that can be used as laboratory models of human diseases, such as mice, rats, etc.
[0218] As used herein, the terms "treat" and "prevent" and words derived therefrom do not necessarily imply 100% or complete treatment or prevention. Rather, there are varying degrees of treatment or prevention that one of ordinary skill in the art recognizes as having potential benefits or therapeutic effects. Moreover, the treatment or prevention provided herein may include the treatment or prevention of one or more conditions or symptoms of the disease being treated or prevented, such as cancer. In addition, for purposes herein, "prevention" may encompass delaying the onset of a disease or its symptoms or conditions.
[0219] The scheme of the present application will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present application and should not be considered as limiting the scope of the present application. If no specific technology or conditions are indicated in the embodiments, the technology or conditions described in the literature in this area or the product specification are carried out. The reagents used or the instruments that do not indicate the manufacturer are all conventional products that can be obtained commercially.
[0220] Example 1: Linear mRNA and circular mRNA plasmid construction, linearization, and in vitro transcription
[0221] 1. Selection of Zika virus and dengue virus antigens
[0222] 1) Based on the ZIKV FSS13025 virus strain (GenBank: JN860885.1), the wild-type M / E antigen (i.e., ZIKV-WT) sequence was obtained, and its amino acid sequence is shown in SEQ ID NO: 13. The 98th amino acid residue D of the wild-type ZIKV-E protein was mutated to N, the 100th amino acid residue G was mutated to T, and the 110th amino acid residue K was mutated to N to translate the glycosylation modification sequence (i.e., ZIKV-NLG), and its amino acid sequence is shown in SEQ ID NO: 1.
[0223] (SEQ ID NO: 13).
[0224] 2) According to the DENV-2 virus strain (GenBank accession number: KM204118.1), the wild-type M / E antigen (ie, DENV-WT) sequence was obtained, and its amino acid sequence is shown in SEQ ID NO: 14. The 98th amino acid residue D of the wild-type DENV-E protein was mutated to N, the 100th amino acid residue G was mutated to T, and the 110th amino acid residue K was mutated to N to translate the glycosylation modification sequence (ie, DENV-NLG), and its amino acid sequence is shown in SEQ ID NO: 2.
[0225] (SEQ ID NO: 14).
[0226] 2. Linear mRNA plasmid construction, linearization, and in vitro transcription
[0227] First, pcDNA3.1 was selected as a plasmid vector, and the nucleotide sequence encoding the antigen of the mRNA vaccine and other DNA expression elements were introduced by conventional molecular biological methods, including, in order from upstream to downstream: (1) T7 promoter; (2) 5' UTR sequence upstream of the coding region (the 5' UTR sequences of several mRNA vaccines were the same, all of which were the sequence shown in SEQ ID NO: 10); (3) signal peptide coding sequence (i.e., SP, as shown in SEQ ID NO: 5); (4) RNA coding sequence of vaccine antigen (the amino acid sequence of ZIKV-WT is shown in SEQ ID NO: 13, the amino acid sequence of ZIKV-NLG is shown in SEQ ID NO: 1, the amino acid sequence of DENV-WT is shown in SEQ ID NO: 14, and the amino acid sequence of DENV-NLG is shown in SEQ ID NO: 2); (5) downstream 3' UTR sequence (the 3' UTR sequences of the two mRNA vaccines were the same, all of which were the sequence shown in SEQ ID NO: 11); (6) and poly-A tail (Poly-A-tail). Finally, the expression plasmids of two Zika virus mRNA vaccines, pcDNA3.1-ZIKV-WT and pcDNA3.1-ZIKV-NLG, and two dengue virus mRNA vaccines, pcDNA3.1-DENV-WT and pcDNA3.1-DEN-NLG, were obtained.
[0228] The above-mentioned in vitro transcription plasmid was digested with restriction endonuclease BstZ17I-HF (New England Biolabs) and linearized; it was purified using a conventional DNA purification method to obtain an in vitro transcription template; based on the template, in vitro transcription was performed using a T7 RNA in vitro transcription kit (HiScribe T7 ARCA mRNA Kit, New England Biolabs) to obtain in vitro transcribed mRNA.
[0229] 3. Circular mRNA plasmid construction, linearization, in vitro transcription, and purification
[0230] See the construction diagram for Figure 1, wherein the structure of the linear circRNA precursor before cyclization is: 5' homology arm 1 + 3' intron (nucleotide sequence as shown in SEQ ID NO: 20), linker2 (nucleotide sequence as shown in SEQ ID NO: 7), 5' homology arm 2 (nucleotide sequence as shown in SEQ ID NO: 18), spacer1 (nucleotide sequence as shown in SEQ ID NO: 10), IRES-EMCV (nucleotide sequence as shown in SEQ ID NO: 6), T7 promoter (nucleotide sequence as shown in SEQ ID NO: 17), signal peptide nucleotide (nucleotide sequence as shown in SEQ ID NO: 16), M / E-NLG (nucleotide sequence as shown in SEQ ID NO: 3 or 4), spacer2 (nucleotide sequence as shown in SEQ ID NO: 9), 3' homology arm 2 (nucleotide sequence as shown in SEQ ID NO: 19), linker1 (nucleotide sequence as shown in SEQ ID NO: 8), 5' intron + 3' homology arm (nucleotide sequence as shown in SEQ ID NO: 21);
[0231] The structure of the circularized circRNA is as follows: linker2 (nucleotide sequence as shown in SEQ ID NO: 7), 5' homology arm 2 (nucleotide sequence as shown in SEQ ID NO: 18), spacer1 (nucleotide sequence as shown in SEQ ID NO: 10), IRES-EMCV (nucleotide sequence as shown in SEQ ID NO: 6), T7 promoter (nucleotide sequence as shown in SEQ ID NO: 17), signal peptide nucleotide (nucleotide sequence as shown in SEQ ID NO: 16), M / E-NLG (nucleotide sequence as shown in SEQ ID NO: 3 or 4), spacer2 (nucleotide sequence as shown in SEQ ID NO: 9), 3' homology arm 2 (nucleotide sequence as shown in SEQ ID NO: 19), linker1 (nucleotide sequence as shown in SEQ ID NO: 8);
[0232] GGGAGACCCTCGACCGTCGATTGTCCACTGGTCAACAATAGATGACTTACAACTAATCGGAAG GTGCAGAGACTCGACGGGAGCTACCCTAACGTCAAGACGAGGGTAAAGAGAGTCCAATTCTCA AAGCCAATAGGCAGTAGCGAAAGCTGCAAGAGAATGAA (SEQ ID NO: 20);
[0233] ATAATTGAGCCTTAAAGAAGAAATTCTTTAAGTGGATGCTCTCAAACTCAGGGAAACCTAAAT CTAGTTATAGACAAGGCAATCCTGAGCCAAGCCGAAGTAGTAATTAGTAAGACCAGTGGACAATCGACGGATAACAGCATATCTAG(SEQ ID NO:21).
[0234] The specific steps are as follows:
[0235] First, the constructed circular RNA sequence (the amino acid sequence of ZIKV-WT is shown in SEQ ID NO: 13, the amino acid sequence of ZIKV-NLG is shown in SEQ ID NO: 1, the amino acid sequence of DENV-WT is shown in SEQ ID NO: 14, and the amino acid sequence of DENV-NLG is shown in SEQ ID NO: 2) is constructed into the PCU57 plasmid, and the restriction endonuclease BstZ17I-HF (New England Biolabs) is used to digest the above-mentioned in vitro transcribed plasmid and linearize it; the conventional DNA purification method is used to purify it to obtain the template for in vitro transcription; the T7 high-yield RNA synthesis kit (New England Biolabs) is used to synthesize unmodified linear mRNA or circRNA precursor from the linearized plasmid DNA template by in vitro transcription. After in vitro transcription, the reaction is treated with DNaseI (New England Biolabs) for 20 minutes. After DNase I treatment, the unmodified linear mRNA is column purified using the MEGAclear Transcription Clean-up kit (Ambion). The RNA was then heated to 70°C for 5 min and immediately placed on ice for 3 min before capping using mRNAcap-2'-0-methyltransferase (New England Biolabs) and vaccinia capping enzyme (New England Biolabs) as directed. A polyadenylation tail was added to the capped linear transcript using Escherichia coli Po1yA polymerase (New England Biolabs) as directed, and the fully processed mRNA was column purified. The purified RNA was recircularized by heating the RNA to 70°C for 5 min and immediately placing it on ice for 3 min before adding alanine aminotransferase (GTP) to a final concentration of 2 mM and a buffer containing magnesium (50 mM Tris-HCl, 10 mM MgCl, 1 mM DTT, pH 7.5). The RNA was then heated to 55°C for 8 min and then column purified. To enrich for circRNA, the RNA was diluted in water and then heated at 65°C for 3 min and cooled on ice for 3 min. 20 U RNase R and 10x RNase R buffer (Epicentre) were added and incubated at 37°C for 15 min; additional 10 U RNase R was added midway through the reaction. RNase R digested RNA was column purified. RNA was separated using 2% agarose gel (Invitrogen); SSRNA ladder (NEB) was used as a standard.
[0236] The constructed circular RNA was purified by high performance liquid chromatography, and the circRNA was heated at 65°C for 3 min and then placed on ice for 3 min. RNA was run on an Agilent 1100 series HPLC (Agilent) through a 4.6×300mm size exclusion column (Sepax Technologies; Part No.: 215980P-4630) with a particle size of 5 μm and a pore size of 200A. RNA was run at a flow rate of 0.3 mL / min in RNase-free TE (10 mM Tris, 0.5 mM EDTA, pH = 6). RNA was detected by ultraviolet absorbance at 260 nm. The resulting RNA fraction was precipitated with 5 M ammonium tartrate, resuspended in water, and then treated with RNaseR in some cases to finally obtain purified circRNA.
[0237] Example 2: Preparation of linear mRNA vaccines and circular RNA vaccines
[0238] See the preparation diagram for Figure 1Using the ethanol injection method, the cationic lipid iLAND (preparation method, see "Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia [J]. Science Advances, 2022, 8 (7): eabm1418. DOI: 10.1126 / sciadv.abm1418."), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), cholesterol and PEGylated lipid (dimyristoyl-rac-glycero-PEG; manufacturer Merck, batch number 880151P) were mixed at a molar ratio of 50:10:38.5:1.5, and the lipid mixture was mixed with 50 mM citrate buffer (pH 4.0) and ethanol (aqueous solution: ethanol) in a ratio of 3:1, mixed with the above mRNA (ZIKV-WT-linear mRNA, ZIKV-NLG-linear mRNA, DENV-WT-linear mRNA, DENV-NLG-linear mRNA, ZIKV-WT-circular mRNA, ZIKV-NLG-circular mRNA, DENV-WT-circular mRNA, DENV-NLG-circular mRNA), packaged and incubated at 50°C for 20 minutes. After packaging, dialyze with PBS for 2 hours. The encapsulation and loading efficiency of LNPs for mRNA was determined using the RiboGreen method, which can quantitatively measure the encapsulated mRNA. The particle size of LNP-mRNA was measured by dynamic light scattering using Malvern Zetasizer Nano-ZS300, and the results were analyzed using Zetasizer V7.13 software to obtain the autocorrelation function. The prepared vaccines were named linear mRNA-ZIKV WT , linear mRNA-ZIKV NLG , linear mRNA-DENV WT , linear mRNA-DENV NLG , circular mRNA-ZIKV WT , circular mRNA-ZIKV NLG , circular mRNA-DENV WT , circular mRNA-DENV NLG Among them, in the following embodiments, DENV WT and DENV NLG Both refer to circular mRNA vaccines, L-DENV WT and L-DENV NLG Both refer to linear mRNA vaccines, L-mRNA NLG Refers to linear mRNA-ZIKV NLG, circRNA WT refers to circular mRNA-ZIKV WT , circRNA NLG refers to circular mRNA-ZIKV NLG .
[0239] Example 3: Evaluation of humoral immunity levels induced by mRNA vaccines in Balb / c mice
[0240] 1. In this example, female Balb / c mice aged 6-8 weeks (from Beijing Vital River Laboratory Animal Technology Co., Ltd.) were used for animal experiments. Figure 2A The experimental groups were: negative control group, circular wild-type RNA group-ZIKV, circular glycosylated RNA vaccine immunization group-ZIKV, circular wild-type RNA group-DENV, and circular glycosylated RNA vaccine immunization group-DENV. All mice in the mRNA vaccine immunization group were immunized with the same designed mRNA vaccine (i.e., ZIKV) on days 0 and 14. WT , ZIKV NLG 、DENV WT 、DENV NLG ), the immunization process and injection dose of the negative control group mice were the same as those of the vaccine group, and the vaccination method was intramuscular injection. The mRNA vaccine group was vaccinated with 5 μg mRNA / mouse. Serum samples of mice were collected at week 1 and week 4. All collected sera were inactivated by incubation at 56°C for 30 minutes, and then frozen in a -80°C refrigerator to test the binding antibody titer of the immune serum and the true virus neutralizing antibody titer.
[0241] 2. The level of humoral immunity induced by mRNA vaccine in mice was detected by testing the binding antibody level and neutralizing antibody level in the serum of the above-mentioned infected mice.
[0242] The binding antibody titer in the sera of immunized mice was detected by ELISA experimental method. The specific method was as follows: DENV-2-E protein (purchased from Sino Biological) or ZIKV E protein (amino acid sequence as shown in SEQ ID NO: 15: IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNGCGLFGKGSLVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGR LSSGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLMCLALGGVLIFLSTAVSA) was diluted to 0.5 μg / ml with ELISA coating solution (sodium carbonate-sodium bicarbonate buffer, pH=9.6), and 100 μl was added to each well of a 96-well ELISA plate and placed at 4°C overnight. The coating solution was discarded the next day, and the ELISA plate was blocked with 5% BSA prepared in D-PBS and placed at 37°C for 2 hours. The serum samples from each experimental group of mice in Example 3 were diluted in a 96-well plate starting from 1:200, and then the dilutions were transferred to the ELISA plate, and then the ELISA plate was incubated at 37°C for 2 hours; the blocking solution was poured out and washed 4 times with PBST. Then, Goat Anti-Mouse HRP secondary antibody (purchased from Kangwei Century) diluted 1:1000 with blocking solution was added, incubated at 37°C for 1 hour, and washed 5 times with PBST. Then, 50μL 3,3',5,5'-tetramethylbenzidine (TMB) substrate was added for color development, and 50μl 2M hydrochloric acid was added after 10 minutes to terminate the reaction, and the OD was detected on an enzyme reader (Bio-Radi Mark). 450The endpoint titer is defined as the serum dilution factor at which the absorbance produced by the serum is 2-3 times greater than the background value. The antibody titer below the detection limit is defined as half of the detection limit.
[0243] The neutralizing antibody titer in the serum of immune mice was detected by microneutralization experiment. The specific method was as follows: VERO cells were plated on 96-well plates one day in advance with DMEM medium (Invitrogen, C11995500BT) containing 1% FBS (Gibco, 10270-106). The next day, when the cells grew to about 90%, the serum of immune mice was diluted in a gradient manner in a 96-well plate with DMEM medium (Invitrogen, C11995500BT) containing 1% FBS (Gibco, 10270-106) (specifically, starting from a 10-fold dilution, the serum was diluted in a 3-fold gradient to obtain a total of 10 dilutions). The virus was also diluted to 6×10 3 FFU / mL; then, 85 μL of each dilution of immune mouse serum and 85 μL of virus dilution were mixed in a round-bottom 96-well plate and incubated at 37°C for 2 hours. Then, the VERO cell plate with a confluence of about 90% was added with the serum and virus mixture prepared above, and DMEM with 2% FBS was added after culturing for 2 hours. The cells were cultured in a 37°C incubator for 4 days. After 4 days, the cell culture plate was removed, the cell pathological changes were observed, and the dilution gradient of the true virus antibody was obtained.
[0244] in, Figure 2B From left to right, 5 μg DENV was inoculated WT 、DENV NLG The DENV-2-E binding antibody and true virus neutralizing antibody titers were measured by orbital blood sampling in the first week after the primary immunization and in the fourth week after the primary immunization of Balb / c mice vaccinated with PBS vaccine.
[0245] Figure 2C From left to right, 5 μg circRNA was inoculated WT , circRNA NLG , L-RNA NLG The DENV-2-E binding antibody and true virus neutralizing antibody titers were measured by orbital blood sampling in the first week after the primary immunization and in the fourth week after the primary immunization of Balb / c mice vaccinated with PBS vaccine.
[0246] Figure 2D From left to right, 5 μg circRNA was inoculated WT , circRNANLG , L-RNA NLG Orbital blood was collected from Balb / c mice that were vaccinated with either PBS or PD-1 vaccine at 10, 16, and 20 weeks after the initial immunization to detect the ZIKV-E binding antibody titer.
[0247] Figure 2E From left to right, 5 μg of circRNA was inoculated WT 、circRNA NLG , L-RNA NLG Orbital blood was collected from Balb / c mice that had been vaccinated with either PBS or PD-1 vaccine at 10, 16, and 20 weeks after the initial immunization to detect the titer of neutralizing antibodies against real virus.
[0248] 3. Take mice 42 days after the first immunization and stimulate them for 10 5 Two days after the inoculation of PFU DENV-2 virus, serum was collected for testing, and the cellular immune response of the inoculated mice was evaluated using ELISPOT kits pre-coated with IFN-γ, TNF-α, and IL-2 (Dayou, China). The results are shown in Figure 3 As shown, the results are expressed as standard errors (n=3), and asterisks indicate significant differences (t-test, *: P<0.05; **: P<0.01; ***: P<0.001. The results showed that the secretion of FN-γ, TNF-α, and IL-2 in the immunized group mice was significantly higher than that in the empty group, indicating that the vaccine of the present application successfully induced dengue virus-specific T cell immune response.
[0249] Example 4: mRNA vaccine induces Ifnar1 - / - Evaluation of humoral immunity in mice
[0250] Since DENV-2 and ZIKV infection in Balb / c mice does not cause death or obvious disease symptoms, in order to better verify the effect of the vaccine, immunodeficient mice Ifnar1 - / - Mice are used as a model of infection with DENV-2 and ZIKV (Lazear, Helen Metal. (2016), vol. 19, 5: 720-30.) to evaluate the mRNA vaccine-induced Ifnar1 - / - The humoral immunity level of mice. Specifically:
[0251] Ifnar1 - / - The mice were randomly divided into 7 groups, of which 3 groups were inoculated with DENV by intramuscular injection. WT 、DENV NLG, PBS vaccine, the immunization dose was 5 μg; 3 groups were respectively vaccinated with circRNAWT, circRNANLG, and L-mRNANLG vaccine by intramuscular injection, the immunization dose was 10 μg, and 1 group of mice was immunized with PBS as a negative control (i.e., PBS group); the immunization procedure was the same as described in Example 3. That is, blood was collected on the 28th day to separate serum, and Ifnar1 was detected by ELISA method - / - Binding antibody titers in mouse sera, using microneutralization assay to detect Ifnar1 - / - The titer of neutralizing DENV-2 antibodies in mouse sera. - / - Mice were challenged with DENV-2 or ZIKV SMGC-1 virus on day 28 after the second immunization. 6 PFU / mouse DENV-2 virus or ZIKV SMGC-1 virus, and then observe the survival status of mice and monitor the changes in body weight every day. Figure 4 and Figure 5 shown.
[0252] in, Figure 4 A shows the weight change curve after DENV-2 virus challenge. Figure 4 B shows the mortality results after DENV-2 virus challenge. Figure 4 A and Figure 4 B shows that the mice in the PBS group began to lose weight gradually on the third day after infection, and all died on the ninth day; WT 、DENV NLG The two groups of mice that received the vaccine did not lose weight after the virus attack, and no deaths occurred in the two groups of mice during the entire experiment; these results show that DENV WT 、DENV NLG The vaccine provided complete protection in mice challenged with the virus.
[0253] Figure 5 A shows the weight change curve after ZIKV-SMGC-1 virus infection. Figure 5 B shows the mortality results after ZIKV-SMGC-1 virus challenge. Figure 5 A and Figure 5 B shows that the weight of mice in the PBS group gradually decreased on the third day after infection, and all died on the eighth day; WT 、circRNA NLG , L-mRNA NLG The three groups of mice that received the vaccine did not lose weight after the virus challenge, and none of the three groups of mice died during the entire experiment. These results indicate that circRNAWT 、circRNA NLG , L-mRNA NLG The vaccine provided complete protection in mice challenged with the virus.
[0254] Example 5: Quantitative analysis of viral load in mouse blood and body
[0255] 1. To test the mRNA vaccine DENV WT 、DENV NLG To determine whether the vaccine can protect mice against viremia caused by viral infection, the blood of mice was collected on the 1st and 3rd day after the virus challenge. Trizol was mixed with 200 μl tissue supernatant or 50 μl mouse blood, and viral RNA was extracted using chloroform. DENV-2 specific quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed using Perfect Start II probe qPCR SuperMix on the Quant Studio 3 Real-Time PCR Detection System (ThermoFisher). DENV-2 primers were designed as follows:
[0256] name sequence DENV2-F GGTTAGAGGAGACCCCTCCC(SEQ ID NO:22) DENV-2R GGCGYTCTGTGCCTGGA(SEQ ID NO:23) DENV-2-Probe FAM-CAGGATCTCTGGTCTYTCCCAGCGT-TAMRA(SEQ ID NO:24)
[0257] Where FAM is 6-carboxyfluorescein and TAMRA is 6-carboxy-4'-methoxyaniline. Viral load, expressed in log10 scale, is calculated as viral copies per gram or per milliliter after standard curve calculation. Viral copies below the limit of detection (LOD) are set as half of the LOD. Figure 6 It can be seen that higher viral loads were detected in the PBS group mice on the 1st and 3rd day after infection, and no virus was detected in the serum of mice immunized with mRNA vaccine on the 1st and 3rd day after infection, which indicates that DENV WT 、DENV NLG The vaccine was able to protect mice well against viremia.
[0258] 2. To detect circRNA of mRNA vaccine WT 、circRNA NLG , L-mRNA NLG To determine whether the vaccine can protect mice against viremia caused by viral infection, the blood of mice was collected on days 3 and 6 after the virus challenge. Trizol was mixed with 200 μl of tissue supernatant or 50 μl of mouse blood, and viral RNA was extracted using chloroform. ZIKV-specific quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed using PerfectStart II probe qPCR SuperMix on a 7500 real-time PCR detection system (Thermo Fisher). ZIKV primers were designed as follows:
[0259]
[0260] Where FAM is 6-carboxyfluorescein and TAMRA is 6-carboxy-4'-methoxyaniline). Viral load, expressed in log10 scale, is calculated as viral copies per gram or per milliliter after standard curve calculation. Viral copies below the limit of detection (LOD) are set as half of the LOD. Figure 7 It can be seen that higher viral loads were detected in the PBS group mice on the 3rd and 6th days after infection, and no virus was detected in the serum of mice immunized with mRNA vaccine on the 3rd and 6th days after infection, which indicates that circRNA WT 、circRNA NLG , L-mRNA NLG The vaccine was able to protect mice well against viremia.
[0261] Example 6: Detection of mRNA vaccine in Ifnar1 - / - Clearing immune effects in mice
[0262] 1. In this embodiment, DENV is detected WT 、DENV NLG Whether the vaccine can provide clearing immunity, the specific steps are as shown in Example 4. On the 7th day after the challenge, the mice were dissected and their spleens were taken. The dissected tissues and organs were added to PBS solution, then ground with a grinder, centrifuged and the supernatant was taken out, RNA was extracted using the method of Example 5, and then RT-PCR was performed on DENV-2 RNA. The results are shown in Figure 4. Fig. 9 shown.
[0263] A certain amount of virus was detected in the spleen of mice in the PBS group, while WT 、DENV NLG No virus was detected in the spleens of the two vaccine groups. In addition, a microneutralization experiment was performed to detect the neutralizing antibody titer in the serum one day before the challenge. The results are as follows: Figure 8 shown.
[0264] 2. In this embodiment, circRNA is detected WT 、circRNA NLG , L-mRNA NLG Whether the vaccine can provide clearing immunity, the specific steps are as shown in Example 4. On the 7th day after the challenge, the mice were dissected and parts of the brain, kidney, liver, spleen and testis were taken. The dissected tissues and organs were added to PBS solution, then ground with a grinder, centrifuged and the supernatant was taken, RNA was extracted using the method of Example 5, and then RT-PCR was performed on ZIKV RNA. The results are shown in Figure 4. Fig.10 shown.
[0265] A certain amount of virus was detected in all five organs of mice in the PBS group, while WT , circRNA NLG , L-mRNA NLG No virus was detected in any tissues or organs of the three vaccine groups. In addition, a microneutralization experiment was performed to detect the neutralizing antibody titer in the serum one day before the challenge. The results are as follows: Figure 5 shown.
[0266] Example 7: Blocking effect of Zika virus in pregnant mice
[0267] In this embodiment, female Ifnar1 - / - Mice received the vaccine as described in Example 4. After 28 days, serum samples were collected, heat-inactivated (56°C, 30 minutes), and used to detect ZIKV-E-specific IgG and MN50. - / - Mouse and male Ifnar1 - / - Mice were paired in individual cages. Vaginal plugs were checked daily, and mice were defined as embryonic day zero (de0.5) when plugs were confirmed. On day 5.5, mice were infected with 1x10 6 PFU ZIKV-SMGC-1 virus. All animals were euthanized on day 13.5. Blood, brain, spleen, placenta, and fetal head were collected from the mothers, and the viral load was measured by qRT-PCR, as described in Example 5. The neutralizing antibody titer in the serum on day 28 was detected by microneutralization experiment. The results are shown in Fig.11 RT-PCR detection of ZIKV RNA was performed, and the results were shown in Fig.12 A certain amount of virus was detected in the six organ tissues of mice in the PBS group, while WT , circRNA NLG , L-mRNA NLG No virus was detected in any tissues and organs of the three vaccine groups of mice.
[0268] Example 8: In vitro test of the ADE effect of serum from Balb / c mice immunized with mRNA vaccine on the virus
[0269] 1. Due to the sequence similarity between ZIKV and DENV, DENV WT 、DENV NLG Whether the vaccine can reduce ADE of DENV. The specific steps are as follows: the heat-inactivated serum of Balb / c mice on day 28 after immunization was serially diluted and then mixed with 100 FFU of DENV-2 (1x10 4PFU) were incubated at 37°C for 1 hour. After that, the serum-antibody-virus complex was added to the K562 cells in a 96-well plate and incubated at 37°C for 2 hours. Subsequently, the cells were covered with DMEM containing 2% heat-inactivated FBS. After 4 days of incubation, the supernatant was removed by centrifugation, blocked, and incubated with Z6 (purchased from Sino Biological) primary antibody at room temperature for 1 hour and Goat Anti-Human lgG (H+L) (purchased from proteintech) secondary antibody at room temperature for 1 hour, and then the proportion of positive cells was detected by flow cytometry. The results are shown in Figure 2. Fig.13 As shown, in the absence of antibody mediation, ZIKV virus cannot infect K562 cells.
[0270] Depend on Fig.13 It can be seen that the serum in the PBS group does not contain antibodies that can bind to ZIKV, so the infection rate of the tested samples is at the background level; DENV WT The mouse serum of the group could mediate the infection of K562 cells with ZIKV serotype virus at a certain concentration; while DENV NLG The infection rates of the samples in the two groups were significantly lower than those of DENV WT group, showing reduced or even eliminated ADE to ZIKV; these results suggest that DENV WT 、DENV NLG Vaccines have the obvious advantage of reducing ADE.
[0271] At the same time, the method shown in Example 3 was used to coat ZIKV-E protein antigen (purchased from Sino Biological) to detect DENV WT 、DENV NLG The binding effect of the vaccine-produced serum on ZIKV-E Fig.13 It can be seen that in addition to DENV WT In addition to the combined effect, the other experimental groups had a clear advantage in reducing ADE.
[0272] 2. Due to the sequence similarity between ZIKV and DENV, circRNA NLG , L-mRNA NLG Whether the vaccine can reduce ADE to DENV, please refer to step 1 of this application for specific steps. Fig.14 As shown, DENV virus cannot infect K562 cells without antibody mediation. Fig.14It can be seen that the serum in the PBS group does not contain antibodies that can bind to DENV, so the infection rate of the detected samples is at the background level; the mouse serum in the circRNAWT group can mediate the infection of K562 cells with the DENV-2 serotype virus at a certain concentration; and the infection rates of the circRNANLG and L-mRNANLG group samples were significantly lower than that of the circRNAWT group, showing a weakening or even elimination of the ADE of DENV-2; these results show that circRNANLG and L-mRNANLG vaccines have obvious advantages in reducing ADE.
[0273] At the same time, the method shown in Example 3 was used to coat DENV-2 / 3 / 4 E protein antigens (purchased from Sino Biological), and the binding effect of serum produced by circRNAWT, circRNANLG, and L-mRNANLG vaccines on DENV-2 / 3 / 4 was detected. Fig.15 It can be seen that except for circRNAWT which has a binding effect, the other experimental groups have obvious advantages in reducing ADE.
[0274] Example 9: In vivo experiments to detect the ADE of the virus in the serum of Balb / c mice immunized with mRNA vaccine
[0275] 1. To further prove that DENV under physiological conditions WT 、DENV NLG Can vaccines reduce ADE of ZIKV? This example is based on Ifnar1 - / - Mouse, verified DENV WT 、DENV NLG The ADE effect of the vaccine on ZIKV. First, the heat-inactivated serum of Balb / c mice on day 28 after immunization was diluted 1:10 to convert Ifnar1 - / - The mice were randomly divided into 3 groups and passively immunized with the mixed serum. DENV WT 、DENV NLG 200 μL of diluted serum was injected into each Balb / c mouse. 24 hours later, ZIKV-SMGC-1 virus was injected subcutaneously. 6 PFU, each mouse was weighed and recorded before injection. The mouse status, survival and body weight were observed every day thereafter. Fig.16 and Fig.17 shown.
[0276] Depend on Fig.16 and Fig.17 It can be seen that DENV WT The overall weight loss of mice in the PBS group and DENV group was significantly higher than that in the NLG More serious, indicating DENVWT Sera from vaccine-immunized mice enhanced infection with ZIKV-SMGC-1, whereas DENV NLG The weight loss trend of mice in the PBS group was consistent with that in the DENV-2E group, which indicates that the glycosylation of DENV-2E protein weakened the production of antibodies that can cause ADE effect on ZIKV, making DENV NLG The performance of mice in the group was similar to that of the PBS group. At the same time, blood was collected from mice on the 1st and 3rd day of challenge for RT-PCR detection, and the method was as shown in Example 5. The design of ZIKV-SMGC-1 primers is shown in Example 5.
[0277] Where FAM stands for 6-carboxyfluorescein and TAMRA stands for 6-carboxy-4'-methoxyaniline. NLG The vaccine can significantly reduce ADE of ZIKV after immunization with the wild-type vaccine.
[0278] 2. To further prove that circRNA under physiological conditions NLG , L-mRNA NLG Can vaccines reduce ADE for DENV? This example is based on Ifnar1 - / - Mouse, verified circRNA NLG , L-mRNA NLG The ADE effect of the vaccine on DENV. First, the heat-inactivated serum of BALB / c mice on day 28 after immunization was diluted 1:10 to convert Ifnar1 - / - The mice were randomly divided into 3 groups and passively immunized with the mixed serum. The circRNA WT 、circRNA NLG , L-mRNA NLG 200 μL of diluted serum was injected into each BALB / c mouse. 24 hours later, DENV2-NGC virus was injected subcutaneously, 10,000 PFU per mouse. Each mouse was weighed and recorded before injection. The mouse status, survival and body weight were observed every day. Fig.18 As shown. Fig.18 It can be seen that circRNA WT The overall weight loss of mice in the PBS group was higher than that of the circRNA NLG , L-mRNA NLG More serious, indicating that circRNA WT Sera from vaccine-immunized mice enhanced DENV-2 infection, while circRNA NLG , L-mRNA NLGThe weight loss trend of mice in the PBS group was consistent with that in the ZIKV E protein group, which indicated that the glycosylation of ZIKV E protein weakened the production of antibodies that could lead to ADE effect against DENV-2, making the circRNA NLG , L-mRNA NLG The performance of mice in the group was similar to that of the PBS group. At the same time, blood was collected from mice on the 3rd and 6th days after the challenge for RT-PCR detection, and the method was shown in Example 5. DENV-2 primer design is shown in Example 5. FAM represents 6-carboxyfluorescein and TAMRA represents 6-carboxy-4'-methoxyaniline. These in vivo experimental results have well demonstrated that circRNA NLG , L-mRNA NLG The vaccine can significantly reduce ADE of DENV-2 after wild-type immunization.
[0279] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present application. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0280] Although the embodiments of the present application have been shown and described above, it can be understood that the above embodiments are exemplary and cannot be understood as limitations on the present application. Ordinary technicians in this field can change, modify, replace and modify the above embodiments within the scope of the present application.
Claims
1. A polypeptide analog, characterized in that: The polypeptide analog comprises a polypeptide and a glycosylation modification, the polypeptide is derived from Zika virus or dengue virus, the glycosylation modification is located at positions 98 to 113 of the polypeptide, and positions 98 to 113 of the polypeptide are NRTWGNGCGLFGNGSL; Optionally, the polypeptide comprises the E protein of Zika virus or dengue virus; And / or, the polypeptide is selected from the M protein and the E protein of Zika virus, or the M protein and the E protein of dengue virus; And / or, the polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or 2.
2. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the polypeptide analog of claim 1; Optionally, the nucleic acid molecule is DNA or RNA; Optionally, the RNA is selected from linear mRNA or circular RNA.
3. An expression vector, characterized in that: The expression vector carries the nucleic acid molecule of claim 2; Optionally, the expression vector is selected from a prokaryotic expression vector or a eukaryotic expression vector.
4. A recombinant cell, characterized in that The recombinant cell carries the nucleic acid molecule of claim 2 or the expression vector of claim 3; or The recombinant cell expresses the polypeptide analog of claim 1.
5. A circular RNA, characterized in that comprising a first nucleic acid sequence encoding a polypeptide; Wherein, the polypeptide is derived from Zika virus or dengue virus, and the 98th to 113th positions of the polypeptide are NRTWGNGCGLFGNGSL.
6. The circular RNA according to claim 5, characterized in that The polypeptide includes the E protein of Zika virus or dengue virus; And / or, the polypeptide is selected from the M protein and the E protein of Zika virus, or the M protein and the E protein of dengue virus; And / or, the polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or 2; And / or, the first nucleic acid sequence has a nucleotide sequence as shown in SEQ ID NO: 3 or 4; Optionally, further comprising a second nucleic acid sequence, the 3' end of the second nucleic acid sequence is connected to the 5' end of the first nucleic acid sequence, and the second nucleic acid sequence is used to encode a signal peptide; Optionally, the signal peptide is a JEV signal peptide; Optionally, the signal peptide has an amino acid sequence as shown in SEQ ID NO: 5; Optionally, further comprising a promoter, wherein the promoter is located at the 5' end of the second nucleic acid sequence; Optionally, the promoter is a T7 promoter; Optionally, further comprising an IRES sequence, wherein the 3' end of the IRES sequence is connected to the 5' end of the second nucleic acid sequence; Optionally, the IRES sequence is selected from at least one of the IRES sequence of EMCV virus, the IRES sequence of CVB3 virus, the IRES sequence of EV71 virus, the IRES sequence of PV virus, and the IRES sequence of CSFV virus; Optionally, the IRES sequence is selected from the IRES sequence of EMCV virus; Optionally, the IRES sequence has a nucleotide sequence as shown in SEQ ID NO: 6; Optionally, it further comprises a polyAC sequence or a polyA sequence, wherein the 3' end of the polyA sequence is connected to the 5' end of the IRES sequence, and the 5' end of the polyAC sequence is connected to the 3' end of the IRES sequence; Optionally, further comprising a 3' exon sequence and a 5' exon sequence, wherein the 3' exon sequence is located at the 5' end of the first nucleic acid sequence and is used to be recognized by the 3' catalytic group I intron fragment, and the 5' exon sequence is located at the 3' end of the first nucleic acid sequence and is used to be recognized by the 5' catalytic group I intron fragment; Optionally, the 3' exon sequence has a nucleotide sequence as shown in SEQ ID NO:7; Optionally, the 5' exon sequence has a nucleotide sequence as shown in SEQ ID NO: 8; Optionally, further comprising a 5' homology arm and a 3' homology arm, wherein the 5' homology arm is located between the 3' exon sequence and the polyA sequence, and the 3' homology arm is located between the 5' exon sequence and the polyAC sequence; Optionally, the 5' homology arm has a nucleotide sequence as shown in SEQ ID NO: 18; Optionally, the 3' homology arm has a nucleotide sequence as shown in SEQ ID NO:
19.
7. A linear mRNA, characterized in that comprising a nucleic acid sequence A encoding a polypeptide; Wherein, the polypeptide is derived from Zika virus or dengue virus, and positions 98 to 113 of the polypeptide are NRTWGNGCGLFGNGSL; Optionally, the polypeptide comprises the E protein of Zika virus or dengue virus; And / or, the polypeptide is selected from the M protein and the E protein of Zika virus, or the M protein and the E protein of dengue virus; And / or, the polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or 2; And / or, the nucleic acid sequence A has a nucleotide sequence as shown in SEQ ID NO: 3 or 4; Optionally, further comprising a nucleic acid sequence B, the 3' end of the nucleic acid sequence B is connected to the 5' end of the nucleic acid sequence A, and the nucleic acid sequence B is used to encode a signal peptide; Optionally, the signal peptide is a JEV signal peptide; Optionally, the signal peptide has an amino acid sequence as shown in SEQ ID NO: 5; Optionally, it further comprises a 5' UTR sequence and a 3' UTR sequence, wherein the 5' UTR sequence is connected to the 5' end of the nucleic acid sequence B, and the 3' UTR sequence is connected to the 3' end of the nucleic acid sequence A; Optionally, the 5' UTR sequence has a nucleotide sequence as shown in SEQ ID NO: 11; Optionally, the 3'-end UTR sequence has a nucleotide sequence as shown in SEQ ID NO: 12; Optionally, further comprising a promoter, wherein the promoter is located at the 5' end of the 5' UTR sequence; Optionally, the promoter is a T7 promoter; Optionally, a polyA sequence is further included.
8. A vaccine, characterized in that It comprises the polypeptide analogue of claim 1, the circular RNA of any one of claims 5 to 6, or the linear mRNA of claim 7; Optionally, further comprising liposomes, neutral lipids, hydrophobic lipids, PEG-lipids; Optionally, the liposome is iLAND; Optionally, the neutral lipid comprises at least one selected from the following: distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DPPC), phosphatidylcholine (POPC), dioleoylphosphatidylethanolamine (DOPE), dilauroylphosphatidylcholine (DLPC), diethylpyrocarbonate (DEPC), dimyristoylphosphatidylcholine (DMPC), and egg yolk phosphatidylcholine (EPC); Optionally, the neutral lipid is selected from dioleoylphosphatidylethanolamine; Optionally, the hydrophobic lipid is selected from sterols, preferably cholesterol; Optionally, the PEG-lipid is selected from at least one of the following: dipalmitoylphosphatidylethanolamine-PEG, distearoylphosphatidylethanolamine-PEG, dimyristylglycerol, and dimethacrylate; Optionally, the PEG-lipid is selected from dimyristylglycerol and / or dimethacrylate; Optionally, the molar ratio of the liposome, the neutral lipid, the hydrophobic lipid, and the PEG-lipid is (20-80):(5-30):(10-50):(0.5-5).
9. A composition, characterized in that It comprises the polypeptide analogue of claim 1, the circular RNA of any one of claims 5 to 6, the linear mRNA of claim 7, or the vaccine of claim 8, and optionally a pharmaceutically acceptable excipient.
10. Use of the polypeptide analogue of claim 1, the circular RNA of any one of claims 5 to 6, the linear mRNA of claim 7, or the vaccine of claim 8, or the composition of claim 9 in the preparation of a medicament for preventing or treating diseases related to Zika virus or dengue virus infection.
